Panel session 17:00
Watch the programGrand Hall
A unifying role of the GxP in the conditions of the changing reality. Part 2
Questions and topics for discussion
• Special aspects of circulation of reference standards
• Crucial issues of good preclinical and good clinical practices
• From generics to innovations. Regulation and production of innovative and high-tech medicines
• The laboratory phase of pharmaceutical development as a fundamental pillar for quality and efficacy of a medicinal product
• Special aspects of batch release testing
The Session Partner: Akhrikhin
Moderator
Roman Drai
R&D Director, Geropharm group of companies
Participants
Miloš Luburić
GMP inspector, Institute for Medicines and Medical Devices (CInMED), Montenegro
Valery Makarov
Director for Science, RMC "Home of Pharmacy"
Natalia Malykh
Vice President for Business Development, the Pharmasyntez Group of Companies
Mahmoud Fawaz Al-Qawasmeh
Head of the Drug Control and Inspection Department, Jordan Food and Drug Administration (JFDA), Jordan
Pavel Burenkov
Deputy Head of the Inspection Authority of the FSI “State Institute of Drugs and Good Practices”, Russian Ministry of Industry and Trade
Du Jing
GMP Inspector, Centre for Food and Drug Inspection (CFDI), China
Dmitry Somov
Acting Director General of the Information Center for Expertise, Accounting and Analysis of Circulation of Medical Products, Russian Federal Service for Surveillance in Healthcare (Roszdravnadzor)
Naala Grivapsh
Corporate Quality Director, Binnopharm Group of Companies
Vladimir Gegechkori
Deputy Director General (Production and Strategic Development), National Centre for Reference Standards
Deon Poovan
Senior Manager: Inspectorate and Regulatory Compliance, South African Health Products Regulatory Authority (SAHPRA), South Africa
Leila Gargoubi
GMP Inspector at Direction of Inspection Department, Ministry of Health, Tunisia
